Sopharma Trading AD (FRA:6YH) Other Stockholders Equity: €89 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6YH Sopharma Trading AD FRA:6YH
82 GF Score
Price €2.74
GF Value €7.38
! 2 Warning Signs
View Full Analysis

What is Sopharma Trading AD Other Stockholders Equity?

Sopharma Trading AD FRA:6YH +0.74% 82 Other Stockholders Equity is €89 Mil as of Mar. 2026. GuruFocus rates FRA:6YH with a GF Score™ of 82/100 and a GF Value™ of €7.38. The stock has 2 warning signs investors should review.

Sopharma Trading AD's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €89 Mil.

Sopharma Trading AD's quarterly Other Stockholders Equity increased from Sep. 2025 (€88 Mil) to Dec. 2025 (€89 Mil) and increased from Dec. 2025 (€89 Mil) to Mar. 2026 (€89 Mil).

Sopharma Trading AD's annual Other Stockholders Equity increased from Dec. 2023 (€50 Mil) to Dec. 2024 (€67 Mil) and increased from Dec. 2024 (€67 Mil) to Dec. 2025 (€89 Mil).

Sopharma Trading AD Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Sopharma Trading AD's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma Trading AD Other Stockholders Equity Chart

Sopharma Trading AD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.92 41.40 50.11 66.79 88.53

Sopharma Trading AD Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.47 88.30 88.30 88.53 88.97
FRA:6YH
82GF Score
Sopharma Trading AD FRA:6YH
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma Trading AD Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €89 Mil mean?
Sopharma Trading AD (FRA:6YH) has a Other Stockholders Equity of €89 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Sopharma Trading AD and its competitors.
Is Sopharma Trading AD's Other Stockholders Equity too high?
Sopharma Trading AD's current Other Stockholders Equity is €89 Mil. Overall, Sopharma Trading AD has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Sopharma Trading AD's Other Stockholders Equity compare to MCK and CAH?
Sopharma Trading AD's Other Stockholders Equity of €89 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Distribution company?
A good Other Stockholders Equity depends on the Medical Distribution industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Sopharma Trading AD and its competitors. Sopharma Trading AD's current Other Stockholders Equity is €89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma Trading AD stock overvalued right now?
Sopharma Trading AD (FRA:6YH) has a current Other Stockholders Equity of €89 Mil. The stock's GF Value™ is €7.38, compared to a current price of €2.74 — trading 62.9% below its estimated fair value. The current Other Stockholders Equity is €89 Mil. Sopharma Trading AD's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Sopharma Trading AD (FRA:6YH), the current Other Stockholders Equity is €89 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma Trading AD (FRA:6YH) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued. The current stock price of €2.74 is trading 62.9% below its estimated GF Value™ of €7.38.

Key valuation signals for FRA:6YH:

  • Other Stockholders Equity: €89 Mil
  • GF Value™: €7.38 vs. price of €2.74 (62.9% below fair value)
  • GF Score™: 82/100 with 2 warning signs

No single metric tells the full story. See the FRA:6YH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sopharma Trading AD Business Description

Other Exchanges SFT:Bulgaria
Address Sunrise Street, Lachezar Stanchev, 5 Sopharma, Business Towers, Building A Floor 12, Sofia, BGR, 1756
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
82GF Score

Get the complete analysis for FRA:6YH

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.74
Price
€7.38
GF Value